Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic & Ophthalmic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RBP4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RBP4 Full-Length Recombinant Protein (WT & Functional Variants). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed. Human, Mouse, Rat, and Cyno orthologs available. | View RBP4 Products |
| Gene Delivery | RBP4 Promise-ORF / Lentivirus. Full-length ORF for stable hepatic secretion cell lines and metabolic cell line construction (hepatocytes, adipocytes). | View RBP4 Products |
| Benchmark Ab | Anti-RBP4 Neutralizing Antibody (Pan-Specific / Humanized). Recombinant positive control for serum quantification, binding blockade, neutralization assays, and immunoassay standardization. | View RBP4 Products |
| Validator | RBP4 siRNA Set. For knockdown verification, target specificity confirmation, and insulin resistance model studies. | View RBP4 Products |
| Complex Partner | TTR (Transthyretin). Forms circulating complex with RBP4; critical for stability assays, retinol transport studies, and counter-screening. | View TTR Products |
| Receptor | STRA6. Cell surface receptor mediating RBP4 signaling and retinol uptake; target for pathway analysis and functional validation. | View STRA6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Retinol Binding Competition | Sequence-verified native conformation proteins; lipocalin beta-barrel structure preserved for ligand pocket accessibility. |
| TTR Complex Disruption | High-purity RBP4 and TTR proteins available as matched pair for heterodimer formation assays and binding kinetic studies. |
| Cross-species Metabolic & Ophthalmic Models | Human/Mouse/Rat/Cyno ortholog proteins with >95% purity; identical endotoxin specifications across species. |
| Serum Stability & PK | Clinical Benchmark Antibodies included for PK/PD assay development and formulation screening. |
| Specificity Control | Validated siRNA included for RBP4-specificity verification in hepatocyte and adipocyte models; TTR counter-screen proteins available. |
Live RBP4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RBP4 therapeutics is intensifying across two major directions: ophthalmology and metabolic diseases. In ophthalmology, first-generation small molecules (e.g., fenretinide derivatives, Tinlarebant from Belite Bio, ALK-001 from Alkeus Pharma) are advancing for Stargardt disease and dry AMD by reducing serum retinol levels and toxic bisretinoid accumulation. In metabolic diseases, RBP4 is recognized as an adipokine linked to insulin resistance, NASH, and T2DM. The next wave of R&D targets specific RBP4 protein-protein interaction inhibitors, including monoclonal antibodies, peptide antagonists, and RNAi therapies that disrupt the RBP4-TTR complex or block STRA6 receptor engagement without systemic retinoid side effects. Key development trends include antibody therapeutics for sub-Q injection, small molecule PPI inhibitors for oral administration, and metabolic combination therapy pairing RBP4 inhibitors with GLP-1 agonists or insulin sensitizers. As first-generation proof-of-concept data emerge, the focus is shifting toward tissue-specific delivery and long-acting formulations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Emerging Biotech (Preclinical) | Type 2 Diabetes, NASH, Insulin Resistance | Species cross-reactivity panel (Human/Cyno/Mouse) for PK/PD; TTR competition assays; epitope mapping |
| Small Molecule (PPI) | Belite Bio, Alkeus Pharma (ophthalmology); Academic/Pharma Partnerships (metabolic) | Stargardt Disease, Dry AMD, Obesity, Cardiovascular | Retinol displacement assays; high-throughput screening with native protein; interaction disruption using high-purity RBP4 & TTR |
| RNAi / ASO | Alnylam, Ionis | Metabolic Syndrome, NAFLD | Knockdown validation with validated siRNA/cells; serum stability testing |
| Peptide / Bispecific | Preclinical Startups | Metabolic Syndrome, Refractory Metabolic Disease | Heterodimer validation; cross-reactive Abs & species panel; serum stability testing |
Key RBP4 Mutations and Functional Insights
RBP4 carries documented mutations that affect its retinol-binding function and disease association:
- dbSNP rs121918584 (in RDCCAS family): Associated with altered retinol metabolism (UniProt P02753 VAR_009276).
- MCOPCB10 variant (VAR_073856): Dramatic reduction in retinol binding; has greater affinity for the TTR complex, potentially altering serum half-life.
- MCOPCB10 variant (VAR_073857): Similar dramatic reduction in retinol binding with increased affinity for the complex, highlighting a region critical for ligand pocket integrity. These mutations underscore the importance of conformational screening in drug discovery, as compounds targeting the retinol-binding pocket may show differential activity against variant proteins.
Molecular Differentiation & Assay Strategy
To develop best-in-class RBP4 therapeutics, molecular differentiation must address affinity, mechanism, delivery, and safety. Key considerations include:
- Affinity & Kinetics: For clearance antibodies, pM affinity is desired; for tissue-penetrating molecules, moderate affinity (nM range) may avoid binding site barrier. Recommended assays: SPR/BLI with high-purity ortholog proteins.
- Mechanism of Action: pH-dependent binding for enhanced antigen clearance; allosteric inhibition vs. competitive retinol pocket blockade; validation of TTR complex disruption and STRA6 signaling inhibition using cell-based assays (JAK2/STAT3 pathway).
- Delivery & Stability: Sub-Q compatibility requires high-concentration stability (>100 mg/mL) and low viscosity; serum stability (>95% at 7 days) is critical.
- Safety & Specificity: Cross-reactivity against lipocalin family members (RBP1, RBP2) must be excluded; epitope selection should spare retinol binding while blocking STRA6 interaction.
TarMart recommends a cascade assay workflow:
- Primary screening: RBP4-TTR SPR binding inhibition.
- Secondary assay: Retinol displacement to confirm binding site (pocket or allosteric).
- Specificity panel: RBP1/RBP2/RBP5 cross-reactivity.
- Functional assay: STRA6-JAK2/STAT3 signaling blockade in reporter cells.
- PK/PD support: Species-specific ELISA using TarMart antibody pairs.
Cross-sell Targets
Based on RBP4's central role in retinol metabolism and insulin resistance, the following associated targets are recommended for combined studies:
- TTR (Transthyretin): Forms the circulating RBP4-retinol complex; essential for stability assays and counter-screening.
- STRA6: Cell surface receptor for RBP4; required for pathway validation and functional assays.
- ADIPOQ (Adiponectin): Adipokine inversely correlated with RBP4; often measured together in metabolic syndrome studies.
- LEP (Leptin): Regulates energy homeostasis; RBP4 levels correlate with leptin resistance.
- CRBP1 (Cellular Retinol Binding Protein 1): Intracellular retinol metabolism node; useful for downstream pathway analysis.
All TarMart RBP4 reagents are manufactured with endotoxin <1 EU/µg, sequence-verified via mass spectrometry, and available in multiple species orthologs to support longitudinal drug discovery programs.